{
    "clinical_study": {
        "@rank": "95829", 
        "arm_group": [
            {
                "arm_group_label": "Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot A)", 
                "arm_group_type": "Experimental", 
                "description": "Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)"
            }, 
            {
                "arm_group_label": "Lesinurad 400 mg Fed (Site 1 and Site 2, Lot A)", 
                "arm_group_type": "Experimental", 
                "description": "Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)"
            }, 
            {
                "arm_group_label": "Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot B)", 
                "arm_group_type": "Experimental", 
                "description": "Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)"
            }, 
            {
                "arm_group_label": "Lesinurad 400 mg Fed (Site 1 and Site 2, Lot B)", 
                "arm_group_type": "Experimental", 
                "description": "Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the relative bioavailability of lesinurad tablets, manufactured at\n      two different sites."
        }, 
        "brief_title": "Lesinurad Tablet Relative Bioavailability", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "A change in manufacturing site of lesinurad tablets has been implemented. This study is\n      intended to evaluate the clinical comparability of lesinurad tablets manufactured at the two\n      different sites by assessing relevant clinical Pharmacokinetics (PK) parameters."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has a body weight \u2265 50 kg (110 lbs) and a body mass index (BMI) \u2265 18 and \u2264 40\n             kg/m2.\n\n          -  Subject has a Screening sUA value \u2264 7.0 mg/dL.\n\n          -  Subject is free of any clinically significant disease that requires a physician's\n             care and/or would interfere with study evaluations or procedures.\n\n          -  Subject has no clinically relevant abnormalities in vital signs, ECG, physical\n             examination or safety laboratory values per the Investigator's judgment.\n\n        Exclusion Criteria:\n\n          -  Subject has a history or clinical manifestations of significant metabolic,\n             hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic,\n             renal, urological, or psychiatric disorders.\n\n          -  Subject has a history or suspicion of kidney stones.\n\n          -  Subject has a history of asthma.\n\n          -  Subject has undergone major surgery within 3 months prior to Day 1.\n\n          -  Subject has donated blood or experienced significant blood loss (> 450 mL) within 12\n             weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to the Screening\n             visit.\n\n          -  Subject has inadequate venous access or unsuitable veins for repeated venipuncture."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986556", 
            "org_study_id": "RDEA594-129"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot A)", 
                    "Lesinurad 400 mg Fed (Site 1 and Site 2, Lot A)", 
                    "Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot B)", 
                    "Lesinurad 400 mg Fed (Site 1 and Site 2, Lot B)"
                ], 
                "intervention_name": "Lesinurad 400 mg (Site 1)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot A)", 
                    "Lesinurad 400 mg Fed (Site 1 and Site 2, Lot A)"
                ], 
                "intervention_name": "Lesinurad 400 mg (Site 2, Lot A)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot B)", 
                    "Lesinurad 400 mg Fed (Site 1 and Site 2, Lot B)"
                ], 
                "intervention_name": "Lesinurad 400 mg (Site 2, Lot B)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Glendale", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91206"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability of Lesinurad Tablets Manufactured at Two Different Sites", 
        "overall_official": {
            "affiliation": "Ardea Biosciences, Inc.", 
            "last_name": "J. Hall, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "PK endpoints in terms of maximum observed concentration (Cmax); time of occurrence of maximum observed concentration (Tmax); area under the plasma concentration time curve (AUC); and apparent terminal half-life (t1/2).", 
            "measure": "PK profile of lesinurad from plasma", 
            "safety_issue": "No", 
            "time_frame": "Day 1 and Day 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986556"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Changes in Laboratory, Electrocardiogram and Vital Signs Parameters", 
            "measure": "Incidence of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "5 weeks"
        }, 
        "source": "Ardea Biosciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ardea Biosciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}